BPC-157 and TB-500 are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Two peptides, one repair question
Ask any group working on tissue-repair pharmacology which two peptides sit on the bench most often, and the answer is almost always the same: BPC-157 and TB-500. They are the field's two most extensively studied recovery compounds, and they are frequently studied together — not because they do the same thing, but because they do different things that appear to complement one another. BPC-157 leans on vascular and cytoprotective signalling; TB-500 leans on the actin cytoskeleton and cell migration. Put the two profiles side by side and the contrast is clean.
| BPC-157 | TB-500 | |
|---|---|---|
| Class / peptide type | Pentadecapeptide (15 aa), gastric-juice-derived fragment | Synthetic heptapeptide (7 aa), thymosin beta-4 fragment |
| Primary mechanism | VEGFR2 upregulation / angiogenesis; FAK-paxillin & JAK2/STAT3 signalling | G-actin sequestration; cell migration; MMP upregulation |
| Structure / MW | Gly-Glu-Pro… 15 residues · ~1419 Da · CAS 137525-51-0 | Ac-LKKTETQ · ~889 g/mol · from 43-aa Tβ4 (gene TMSB4X) |
| Notable property | Stable in gastric acid | High-affinity G-actin binding (Kd ~0.7 µM) |
| Main research focus | GI mucosa, tendon/ligament, musculoskeletal, CNS | Wound healing, cardiac, corneal, musculoskeletal |
| Typical pairing | Commonly co-studied with TB-500 | Commonly co-studied with BPC-157 |
| Regulatory status | Not FDA-approved · FDA Category 2 (2023) · WADA-prohibited | Not FDA-approved · FDA Category 2 (2023) · WADA-prohibited (S0) |
BPC-157: the angiogenic repair peptide
BPC-157 (Body Protection Compound-157, also coded PL 14736) is a synthetic pentadecapeptide — a 15-amino-acid fragment derived from a protein isolated in human gastric juice. With over thirty years of published preclinical work behind it, it is one of the most extensively studied tissue-repair peptides in the literature. Its mechanistic signature is angiogenic: BPC-157 upregulates the VEGFR2 receptor, driving the formation of new blood vessels, and since new vascular supply is a rate-limiting step in repair, that single action plausibly underwrites much of its observed activity across models. It also engages the FAK-paxillin and JAK2/STAT3 pathways governing fibroblast migration and matrix synthesis, modulates nitric oxide, and suppresses pro-inflammatory cytokines such as TNF-α.
Two features set it apart. First, its research breadth: BPC-157 was first characterised in gastrointestinal biology — gastric and intestinal mucosa, lesion and IBD models — before the tendon, ligament, muscle and central-nervous-system work followed. Second, its unusual acid stability, which means it is not readily degraded in gastric conditions, a property rare among peptides of its class. Researchers sourcing material can buy BPC-157 UK at ≥99% purity with a COA; the full mechanistic profile lives on our BPC-157 knowledgebase page.
TB-500: the actin-binding migration peptide
TB-500 is a synthetic heptapeptide, Ac-LKKTETQ, corresponding to the actin-binding domain of thymosin beta-4 (Tβ4) — a 43-amino-acid protein present in virtually all nucleated mammalian cells and encoded by the TMSB4X gene. Rather than reproduce the whole parent molecule, TB-500 isolates the short motif responsible for its cytoskeletal action. That action is G-actin sequestration: by binding monomeric actin with high affinity (Kd ~0.7 µM), TB-500 shifts the G/F-actin equilibrium that governs how cells build lamellipodia and filopodia and, through them, how they migrate through tissue. It also transiently raises matrix metalloproteinase (MMP-1, -2, -9) activity, helping remodel the extracellular matrix as repair cells move.
The research emphasis reflects that mechanism. TB-500 and full Tβ4 have been studied in dermal wound models — including the Philp work showing the LKKTETQ fragment promoted repair in aged animals comparably to the parent protein — as well as cardiac progenitor migration, corneal epithelial repair, and musculoskeletal tendon and ligament models. One 2024 analytical study even suggested some of the observed activity may be metabolite-mediated rather than down to the parent peptide alone. Material to buy TB-500 UK is supplied at ≥99% purity, and the TB-500 knowledgebase page covers the actin biology in full.
What the differences mean in a research context
Read the table across and the two peptides barely overlap at the mechanistic level. BPC-157 acts on the blood supply and signalling side of repair — angiogenesis via VEGFR2, cytoprotection, cytokine modulation. TB-500 acts on the cell-movement side — actin dynamics, migration, matrix remodelling. Repair, in a preclinical model, needs both: a tissue has to recruit cells to the injury and grow the vasculature to sustain them. That is precisely why the pair is so often studied together, and why the source literature describes them as mechanistically complementary rather than redundant.
Their structures underline the point. BPC-157 is the larger, gastric-derived 15-mer with distinctive acid stability; TB-500 is a compact 7-mer lifted from a much larger endogenous protein. The research footprints diverge accordingly — BPC-157 carries the deeper gastrointestinal and neurological body of work, TB-500 the wound-healing, cardiac and corneal lines. Where they converge is the musculoskeletal setting: tendon, ligament and muscle models feature both, which is the natural home of the combined-repair question.
A caveat researchers should keep in view: for both compounds the evidence base is overwhelmingly preclinical — cell culture and animal models — with limited human data. Both are unapproved, both sit on the FDA's 2023 Category 2 compounding list, and both are prohibited under WADA. Preclinical data does not establish safety or efficacy in humans, and nothing here is dosing or therapeutic guidance.
The bottom line
BPC-157 and TB-500 are not rivals so much as counterparts: one an angiogenic, gastric-derived pentadecapeptide, the other an actin-binding fragment of thymosin beta-4. They target different stages of the same repair process, which is exactly why the "BPC-157 vs TB-500" question so often resolves into "BPC-157 and TB-500." For research-grade material, see our dedicated pages to buy BPC-157 UK and buy TB-500 UK, each ≥99% purity with a COA.